A Look at the Health of the HealthCare Sector: Complementary Research on Horizon Pharma, Enzon Pharmaceuticals, Momenta Pharmaceuticals, Athersys, and Pernix Therapeutics
NEW YORK, April 21, 2015 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
Moments ago, Analysts Review released new research updates concerning several important developing situations including Horizon Pharma Plc (NASDAQ: HZNP), Enzon Pharmaceuticals Inc. (NASDAQ: ENZN), Momenta Pharmaceuticals Inc. (NASDAQ: MNTA), Athersys Inc (NASDAQ: ATHX), and Pernix Therapeutics Holdings Inc (NASDAQ: PTX). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
To access our full PDF reports on a complementary basis, please visit the links below.
--
Today's update concerns the following companies:
============
Full PDF Download Links (you may have to copy and paste the following links into your browser):
HZNP Research Report: ( http://get.analystsreview.com/pdf/?c=Horizon%20Pharma&d=21-Apr-2015&s=HZNP ),
ENZN Research Report: ( http://get.analystsreview.com/pdf/?c=Enzon%20Pharmaceuticals&d=21-Apr-2015&s=ENZN ),
MNTA Research Report: ( http://get.analystsreview.com/pdf/?c=Momenta%20Pharmaceuticals&d=21-Apr-2015&s=MNTA ),
ATHX Research Report: ( http://get.analystsreview.com/pdf/?c=Athersys%20Inc&d=21-Apr-2015&s=ATHX ),
PTX Research Report: ( http://get.analystsreview.com/pdf/?c=Pernix%20Therapeutics&d=21-Apr-2015&s=PTX ).
============
--
Analyst Update: Public Offering, Results, FDA Approvals, and Updated Guidance
Reviewed by: Rohit Tuli, CFA®
U.S. stocks rallied on Monday, triggered by some good first-quarter earnings reports. The NASDAQ gained 1.27% or 62.79 points, to finish at 4,994.60; the Dow Jones Industrial Average advanced 1.17%, or 208.63 points to 18,034.93, and the S&P 500 ended the session at 2,100.40, up 0.92% or 19.22 points. The gains were broad based as all the sectors closed the session in positive. European stocks too edged higher on Monday, as aggressive easing policy in China offsets the impact of Greece turmoil. Major European markets ended the session higher, as Germany's DAX rose 1.74%; France's CAC advanced 0.86%, and Britain's FTSE 100 jumped 0.82%. Meanwhile, Asian markets mostly disappointed on Monday, amid rising concern over slowdown in the Chinese economy. The Shanghai Composite and Japan's Nikkei both closed lower.
On April 16, 2015, shares of Horizon Pharma Plc gained 4.98% to close at $30.97, gaining almost one and a half dollars for the day. On April 15, 2015, the Company announced the pricing of its underwritten public offering of 15,350,000 of its ordinary shares at a price to the public of $28.25 per share.
Enzon Pharmaceuticals Inc. filed its Form 10-K for the year ended December 31, 2014 on March 5, 2015. As per the filing, the revenues for the year were down by 9.6% to $31.17 million as compared to the last year's figure of $34.49 million.
On April 16, 2015, shares of Momenta Pharmaceuticals Inc. rose by 6.09% to end the day at $17.08 after the Company announced that the U.S. Food and Drug Administration has granted marketing approval of Sandoz's Abbreviated New Drug Application for once daily Glatopa™ (glatiramer acetate injection, formerly M356) 20 mg/mL, a generic equivalent of daily COPAXONE® 20 mg.
Athersys Inc came out with its numbers for the fourth quarter and the fiscal year ended December 31, 2014 on March 12, 2015. For the three months ended December 31, 2014, total revenues were $0.2 million compared to $0.9 million in the same period in 2013, reflecting a decrease in contract revenues and grant revenue.
On April 16, 2015, shares of Pernix Therapeutics Holdings Inc were down by 16.35% and closed at $8.34. On the previous day, the Company had updated its full-year 2015 net sales guidance and business outlook.
--
About Analysts Review
At Analysts Review, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.
Analysts Review was designed for investors. By providing the best information available, we have set ourselves apart as one of the premier online investor communities.
--
Editor Note: This is not company news. We are an independent source and our views do not reflect the companies mentioned.
Compliance Procedure: Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA®. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
Further Resources: For more information about this release including editorial notes, compliance procedures and legal disclosures, please visit: http://www.analystsreview.com/editors
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article